公开(公告)号：US20240245838A1

公开(公告)日：2024-07-25

申请号：US18424827

申请日：2024-01-28

Applicant: SINO MEDICAL SCIENCES TECHNOLOGY INC.

Inventor： Jianhua SUN ,  Christophe BUREAU ,  Wenbin CAI ,  Tianzhu LI ,  Xiaoran KANG

IPC: A61L31/16 ,  A61F2/82 ,  A61K31/337 ,  A61K31/436 ,  A61L31/10 ,  A61L33/18 ,  B05D1/00 ,  B05D1/02 ,  B05D3/04

CPC classification number: A61L31/16 ,  A61F2/82 ,  A61K31/337 ,  A61K31/436 ,  A61L31/10 ,  A61L33/18 ,  B05D1/002 ,  B05D1/02 ,  B05D3/0486 ,  A61L2300/256 ,  A61L2300/258 ,  A61L2300/412 ,  A61L2300/416 ,  A61L2300/604 ,  A61L2420/08

Abstract: Drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent are disclosured. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate, disappear between 45 days and 60 days after stent implantation. Stents may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and or MACE.

公开(公告)号：US20180042738A1

公开(公告)日：2018-02-15

申请号：US15797862

申请日：2017-10-30

Applicant: SINO MEDICAL SCIENCES TECHNOLOGY INC.

Inventor： Jianhua SUN ,  Christophe BUREAU ,  Wenbin CAI ,  Tianzhu LI ,  Xiaoran KANG

IPC: A61F2/82 ,  A61L31/02 ,  A61L31/16 ,  A61L31/10

CPC classification number: A61F2/82 ,  A61F2250/0067 ,  A61L31/022 ,  A61L31/06 ,  A61L31/10 ,  A61L31/148 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/608 ,  A61L2420/02 ,  A61L2420/06 ,  C08L67/04

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipate/disappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.

公开(公告)号：US20210361449A1

公开(公告)日：2021-11-25

申请号：US17322829

申请日：2021-05-17

Applicant: SINO MEDICAL SCIENCES TECHNOLOGY INC.

Inventor： Jianhua SUN ,  Christophe BUREAU ,  Wenbin CAI ,  Tianzhu LI ,  Xiaoran KANG

IPC: A61F2/82 ,  A61L31/16 ,  A61L31/10 ,  A61L31/02 ,  A61L31/06 ,  A61L31/14

Abstract: The present disclosure relates to drug eluting stents, methods of making, using, and verifying long-term stability of the drug eluting stents, and methods for predicting long term stent efficacy and patient safety after implantation of a drug eluting stent. In one embodiment, a drug eluting stent may include a stent framework; a drug-containing layer; a drug embedded in the drug-containing layer; and a biocompatible base layer disposed over the stent framework and supporting the drug-containing layer. The drug-containing layer may have an uneven coating thickness. In addition or in alternative, the drug-containing layer may be configured to significantly dissolve/dissipateldisappear between 45 days and 60 days after stent implantation. Stents of the present disclosure may reduce, minimize, or eliminate patient risks associated with the implantation of a stent, including, for example, restenosis, thrombosis, and/or MACE.